UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to _____ Commission File No. 001-36913 Zevra Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-5894398 (State or Other Jurisdiction of I ...

KemPharm, Inc. (KMPH) Q3 2022 Results Conference Call November 9, 2022 5:00 PM ET Company Participants Nichol Ochsner - Vice President of Investor Relations Travis Mickle - President and Chief Executive Officer LaDuane Clifton - Chief Financial Officer Conference Call Participants Sumant Kulkarni - Canaccord Jonathan Aschoff - Roth Capital Partners Operator Good afternoon, and welcome to the KemPharm Third Quarter 2022 Corporate and Financial Results Conference Call. Currently, all callers have been placed ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Commission File No. 001-36913 KemPharm, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-5894398 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 1180 Celebration Boulevard, Suite 103, Celebration, FL 3474 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File No. 001-36913 KemPharm, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-5894398 (State or Other Jurisdiction of Inco ...

KemPharm, Inc. (KMPH) Q2 2022 Earnings Conference Call August 11, 2022 5:00 PM ET Company Participants Nichol Ochsner - Vice President-Investor Relations & Corporate Communications Travis Mickle - President & Chief Executive Officer Perry Sternberg - Chief Executive Officer, Corium Inc. LaDuane Clifton - Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Operator Good afternoon, and welcome to the KemPharm Second Quarter 2020 Corporate and Financial Results Confere ...

Management Presentation May 2022 11 Trademarks herein are held by their respective owners. Cautionary Note Regarding Presentation Information This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forwardlooking statements include all statements that do not relate solely to historical or current facts, including without limitation and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," "an ...

Management Presentation March 2022 11 Trademarks herein are held by their respective owners. Cautionary Note Regarding Presentation Information This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation and can be identified by the use of words such as "may," "will," "expect," "project," "estimate," ...

KemPharm, Inc. (KMPH) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants Travis Mickle - Co-Founder, President, CEO & Director LaDuane Clifton - CFO, Secretary & Treasurer Conference Call Participants Jason Rando - Tiberend Strategic Advisors Operator Thank you for standing by, and welcome to the KemPharm First Quarter 2022 Results Conference Call. [Operator Instructions]. I would now like to hand the call over to your host, Jason Rando with Tiberend Strategic Advisors. Please go ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission File No. 001-36913 KemPharm, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-5894398 (State or Other Jurisdiction of Inc ...

KemPharm, Inc. (KMPH) Q4 2021 Earnings Conference Call March 30, 2022 5:00 PM ET Company Participants Jason Rando - Tiberend Strategic Advisors Travis Mickle - President and CEO LaDuane Clifton - CFO Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Operator Thank you for standing by, and welcome to KemPharm Fourth Quarter and Year-End 2021 Results Conference Call. [Operator Instructions] Please be advised that today's conference may be recorded. [Operator Instructions] I would now like ...